[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chemotherapy-induced-peripheral-neuropathy-in-breast-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chemotherapy-induced-peripheral-neuropathy-in-breast-cancer":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,54],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100621214","the-influence-of-chemotherapy-on-position-sense-100621214",false,"NCT07367711","The Influence of Chemotherapy on Position Sense","Multifaced Approach of Assessing Upper Extremity Proprioception in Breast Cancer Patients With Chemotherapy-Induced Peripheral Neuropathy","ProprioCIPN","Inclusion Criteria\n\nGeneral (applies to all participants):\n\n* At least 18 years of age at the time of signing the informed consent form\n* Voluntary written informed consent of the participant has been obtained prior to any screening procedures\n\nBreast cancer surgery-only patient group:\n\n* The patient is an adult oncological person between 18 and 75 years old who has been treated for cancer\n* The participant has undergone breast cancer surgery but has not received any radiotherapy or chemotherapy treatment (yet).\n* The first session takes place between two and six weeks after breast cancer surgery.\n* The second session takes before any follow-up treatment for breast cancer (radiotherapy or chemotherapy).\n\nChemotherapy group:\n\n* The patient is an adult oncological person between 18 and 75 years old who has been treated for cancer.\n* The participant has undergone breast cancer surgery but has not received any radiotherapy (yet).\n* Participant has a history of treatment with platinum- or taxane-based chemotherapeutic agents, and this treatment has been terminated no later than 6 weeks before the first session.\n\nHealthy control group:\n\n* No history of cancer or chemotherapy treatment\n* Sex and age-matched to patient sample\n\nExclusion Criteria:\n\nGeneral (applies to all participants):\n\n* Participant has a history of mental or physical disorders or neurological disease beyond those related to cancer treatments.\n* Participant uses any prescription or non-prescription drugs on a regular basis which, in the investigator's opinion, might confound the results of the study.\n* Participant is currently participating or has been involved in testing an investigational drug in another clinical study within the last 4 weeks which, in the investigator's opinion, might confound the results of the study.\n* Participant suffered from peripheral neuropathy prior to the chemotherapeutic treatment (Only for patients).\n* Participant has (a history of) a lesion in the central nervous system that is known to possibly cause neuropathic pain: e.g. spinal cord injury, infarction localized in the brainstem or thalamus, syringomyelia, multiple sclerosis, or any other disorder of the CNS that, in the investigator's opinion, may cause neuropathic pain.\n* If applicable: Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive",true,"ALL","18 Years","75 Years",{"count":22,"type":23},145,"ESTIMATED","OBSERVATIONAL","Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most prevalent side-effects of chemotherapy, causing sensory and motor symptoms in patients. CIPN development is especially prevalent in chemotherapy treatment involving platinum- and taxane-based agents. The accompanying pain and deficits greatly impact the quality of life of these patients. Currently, patients are assessed for altered somatosensory using quantitative sensory testing (QST). The German Research Network on Neuropathic Pain (DFNS) has developed a standardized protocol which has been internationally recognized as approach for performing the QST. However, for proprioception the QST is limited to vibration assessments, making it limited as the only test to measure proprioception. Therefore, a comprehensive assessment of the proprioceptive functions is needed to better understand the influence CIPN has on the proprioception of patients, and thereby their quality of life.\n\nIn this project the effects of chemotherapy on somatosensory and proprioceptive functioning of breast cancer patients will be assessed in a cross-sectional study. This will be tested by comparing two groups of breast cancer patients and a healthy control group. Both patient groups will have undergone surgery for breast cancer, however, only one group will be tested after undergoing additional chemotherapy treatment. Thereby, the effects of chemotherapy between the surgery-only patient group and the chemotherapy patient group can tested. Furthermore, the investigators will compare both patient groups to sex- and age-matched healthy controls.",[27,28,29],"CIPN - Chemotherapy-Induced Peripheral Neuropathy","Chemotherapy-Induced Peripheral Neuropathy","Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer",[31,32,33,34,28,35,36,37,38,39,40],"Proprioception","Position Sense","CIPN","Breast Cancer","Motor Control","Motion Capture","Marker-less","QST","Quantitative Sensory Testing","Robotic Assessment","NOT_YET_RECRUITING","2026-01-19",{"date":44,"type":45},"2026-01-26","ACTUAL",{"date":47,"type":23},"2026-02",{"date":49,"type":23},"2027-11",{"name":51,"class":52},"KU Leuven","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":61,"minAge":19,"maxAge":20,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":69,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":53},"100600024","efficacy-of-auricular-acupuncture-therapy-in-the-prevention-of-cipn-in-breast-cancer-100600024","NCT07092111","Efficacy of Auricular Acupuncture Therapy in the Prevention of CIPN in Breast Cancer","Efficacy of Auricular Acupuncture Therapy Via the Seirin Pyonex Needles in the Prevention of Chemotherapy-Induced Peripheral Neuropathy(CIPN) in Breast Cancer","Inclusion Criteria:\n\n* Patients with breast cancer diagnosed with stage I-III;\n* Planned to receive 4 cycles of taxane chemotherapy and have not taken neurostable drugs within three months;\n* 18 years old≤ age≤ 75 years old, female;\n* Subjects voluntarily participate in this trial and sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients who have had acupuncture treatment in the past;\n* After examination by a doctor, there is a local infection at or near the acupuncture site, which is not suitable for acupuncture.\n* Platelets\\\u003C 50,000\u002FμL;\n* Patients with CIPN≥1 grade 1 (NCI-CTCAE);\n* Peripheral neuropathy or other neuropathic pain caused by diabetes mellitus or other factors related to HIV infection.","FEMALE",{"count":63,"type":23},110,"INTERVENTIONAL",[66],"NA","Evaluate the Efficacy of Auricular Acupuncture Therapy via the Seirin Pyonex Needles in the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer",[29],[70,71,72],"chemotherapy-induced peripheral neuropathy","auricular acupuncture","breast cancer","RECRUITING","2025-07-21",{"date":76,"type":45},"2025-07-29",{"date":78,"type":45},"2024-07-01",{"date":80,"type":23},"2025-09",{"name":82,"class":52},"The First Affiliated Hospital with Nanjing Medical University"]